GNFT News

Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH biotech, Cirius Therapeutics (CSTX), is in the IPO pipeline, but before this year, the last biotech IPO targeting NASH came in...read more

All eyes were on Lyft (LYFT) as it priced its IPO, along with two biotechs, Genfit (GNFT) and Precision BioSciences (DTIL), in a week that saw positive IPO returns across the board. 8i Enterprises Acquisition (JFKKU) a blank check targeting a high-growth business in Asia also priced its IPO this...read more

Genfit, a Phase 3 French biotech developing therapies for NASH, raised $135 million by offering 6.65 million ADSs at $20.32 per ADS. It had previously filed to raise $132 million by offering 5.0 million ADSs at $26.33. Genfit plans to list on the Nasdaq under the symbol GNFT. SVB Leerink and Barclays acted as lead managers on the deal....read more

The long-awaited IPO of rideshare giant Lyft (LYFT) will finally hit the market in the week ahead. In total, three IPOs plan to raise roughly $2.3 Billion in the IPO market, a further signal of an IPO market continuing to heat up after roughly $858 million was raised last week led by Levi Strauss (LEVI). A blank check company is also expected to list this...read more